Tracks how long adults with rheumatoid arthritis stay on newer arthritis drugs
Follows adults with rheumatoid arthritis taking targeted or biologic drugs over time.
Plain-language title generated from the registry record
Registry title: Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Key facts
- Where
- Seville, SpainSee the site
Where in Spain
- Hospital Universitario Virgen MacarenaSeville, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Trial code
- NCT05062421
- Record updated
- 17 November 2021
- Original description
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).Read full original descriptionShow less
Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).
These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Inclusion: Patients aged ≥18 years; With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria; Who have received at least one of the doses of the study drugs; In follow-up in the consultations of the UGC of Rheumatology of the HUVM; With at least two complete evaluations (baseline and final) of clinical variables.
Exclusion: Patients where the medical records lack sufficient baseline and final variables to perform the analysis; Patients in whom more than 50% of the variables to be collected are missing in the data collection.